The viability of HIF-1/2-deficient Hepa-c4 cells and tumours suggests that tumour proliferation will still be possible, even with both the HIF-1 and HIF-2 pathways suppressed, because alternative signalling and metabolic pathways can be activated. This evidence concerns the gene HIF1A and neoplasm.